200120172020

Hepatitis (C)an’t wait: taking a de-centralized approach to cure the epidemic

Tom Owen, Ugo Battaglia, and Natasha Cowan | 27 July 2021

Hero image

Hepatitis C is a curable disease, so why are so many countries off track to achieve the World Health Organization elimination target? This World Hepatitis Day, we compare several countries’ approaches to combatting the disease and explore the importance of a de-centralized strategy that overcomes the stigma preventing patients from seeking treatment.

This year’s World Hepatitis Day theme, ‘Hepatitis Can’t Wait,’ stresses the urgency of testing and treating viral hepatitis, as well as removing the stigma surrounding the disease and providing support for patients.

Treatment for hepatitis C has evolved dramatically over the past decade. The introduction of direct-acting-antivirals has revolutionized the treatment landscape, leading the World Health Organization to set a global target to eliminate the disease as a public health problem by 2030.

Today hepatitis C is a curable disease. It takes just 8–12 weeks of oral therapy to successfully cure close to 100% of patients with chronic hepatitis C virus infection. Gone are the days of thrice-weekly injections, low cure rates, and a myriad of side effects. The treatment algorithm is far simpler, the therapies are less invasive, the side effects typically milder and much less frequent, and the time patients spend taking medication is far shorter. There is limited need for pre-treatment assessments, on-treatment monitoring, and post-treatment follow-up, making it much easier for patients to fit treatment into their daily lives.

Despite huge advances in the field, the burden of hepatitis C remains a significant public health problem. The World Health Organization (WHO) estimates that 71 million people globally have chronic hepatitis C.[1] Yet, 80% are unaware of their infection status, and a significant number of those will develop cirrhosis or liver cancer if not treated.[2] So, if a cure exists, why are so many people still infected with hepatitis C virus and suffering from the consequences of ongoing chronic infection and liver damage?

Download the full article to learn about: 

  • The approaches different countries are taking to eliminating hepatitis C
  • Successful strategies for engaging hard-to-reach patients
  • Why treating patients in active addiction is crucial for tackling the disease
  • Iceland case study

Download the PDF of the full article below

Latest articles

News

Fishawack Health Announces New CEO Jonathan Koch

16 September 2021

Thought Leadership

10 tips for a faster life science launch

14 September 2021

News

Paving the way for the next generation of healthcare communicators

01 September 2021

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Fishawack Health website, such as the pages you visit.

For more information, check the cookie statement

Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on fishawack.com, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on Fishawack.com.

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.